^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    PGR (Progesterone receptor)

    i
    Apply
    Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer (NCT04243616)
    Phase 2
    Medical College of Wisconsin
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    03/05/2020
    Primary completion :
    07/14/2025
    Completion :
    08/13/2025
    HER-2 • PD-L1 • PGR • PD-L2
    |
    PD-L1 expression • HER-2 negative • PGR positive
    |
    carboplatin • albumin-bound paclitaxel • cyclophosphamide • pegylated liposomal doxorubicin • Libtayo (cemiplimab-rwlc) • cyclophosphamide intravenous • doxorubicin liposomal
    Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer (S2206) (NCT06058377)
    Phase 3
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    11/27/2023
    Primary completion :
    05/31/2026
    Completion :
    05/31/2026
    HER-2 • ER • PGR
    |
    HER-2 positive • ER positive • HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    Imfinzi (durvalumab) • paclitaxel • doxorubicin hydrochloride • cyclophosphamide • daunorubicin
    Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy (NCT02945579)
    Phase N/A
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    01/20/2017
    Primary completion :
    01/31/2026
    Completion :
    01/31/2026
    ER • PGR
    |
    HER-2 positive • HER-2 negative • PGR positive
    Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET) (NCT05063786)
    Phase 3
    Spanish Breast Cancer Research Group
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    09/14/2021
    Primary completion :
    06/01/2025
    Completion :
    06/01/2025
    HER-2 • ER • PIK3CA • PGR
    |
    ER positive • PIK3CA mutation
    |
    Herceptin (trastuzumab) • capecitabine • Piqray (alpelisib) • fulvestrant • Halaven (eribulin mesylate) • vinorelbine tartrate • Navelbine oral (vinorelbine tartrate oral)
    The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread (NCT03659136)
    Phase 2
    Boehringer Ingelheim
    Completed
    Last update posted :
    02/24/2025
    Initiation :
    11/28/2018
    Primary completion :
    08/30/2021
    Completion :
    05/11/2022
    HER-2 • PGR
    |
    HER-2 negative • PGR positive
    |
    everolimus • exemestane • xentuzumab (BI-836845)
    Hypofractionated Regional Nodal Irradiation Clinical Trial for Women With Breast Cancer (HeNRIetta) (NCT02515110)
    Phase N/A
    Virginia Commonwealth University
    Active, not recruiting
    Last update posted :
    02/21/2025
    Initiation :
    08/04/2015
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    HER-2 • ER • PGR
    QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine (NCT03554109)
    Phase 2
    ImmunityBio, Inc.
    Withdrawn
    Last update posted :
    02/21/2025
    Initiation :
    09/01/2018
    Primary completion :
    06/01/2020
    Completion :
    02/09/2022
    HER-2 • ER • PGR
    |
    HER-2 overexpression • HER-2 amplification
    |
    5-fluorouracil • Bavencio (avelumab) • albumin-bound paclitaxel • cyclophosphamide • leucovorin calcium • Anktiva (nogapendekin alfa inbakicept-pmln) • ETBX-011 • ETBX-051 • ETBX-061 • GI-4000 • GI-6207 • GI-6301 • NK92-CD16-158V • aldoxorubicin (INNO-206)
    Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer (NCT04052555)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/21/2025
    Initiation :
    09/24/2020
    Primary completion :
    11/20/2025
    Completion :
    11/20/2025
    HER-2 • ER • PGR
    |
    HER-2 negative
    |
    berzosertib (M6620)
    Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer (NCT04345913)
    Phase 1/2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/21/2025
    Initiation :
    03/01/2021
    Primary completion :
    06/30/2025
    Completion :
    06/30/2025
    ER • PIK3CA • PGR • PTEN
    |
    HER-2 amplification • HER-2 negative • PIK3CA mutation
    |
    Halaven (eribulin mesylate) • Aliqopa (copanlisib)
    Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer (NCI-2021-11793) (NCT05111561)
    Phase 1
    National Cancer Institute (NCI)
    Suspended
    Last update posted :
    02/21/2025
    Initiation :
    08/02/2022
    Primary completion :
    03/14/2025
    Completion :
    03/14/2025
    HER-2 • KRAS • BRAF • ER • PGR • NRAS • HRAS • NF1
    |
    BRAF mutation • HER-2 amplification • HRAS mutation • BRAF fusion
    |
    Mektovi (binimetinib) • ZEN-3694
    Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma (NCT00740805)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/20/2025
    Initiation :
    08/18/2008
    Primary completion :
    09/03/2021
    Completion :
    10/22/2025
    HER-2 • ER • PGR • BRCA1 • BRCA
    |
    HER-2 negative • BRCA mutation
    |
    doxorubicin hydrochloride • cyclophosphamide • veliparib (ABT-888) • cyclophosphamide intravenous
    Tracking Triple-negative Breast Cancer Evolution Through Therapy (TRACERX-TNBC) (NCT03077776)
    Phase N/A
    UNICANCER
    Active, not recruiting
    Last update posted :
    02/20/2025
    Initiation :
    04/14/2017
    Primary completion :
    06/01/2024
    Completion :
    05/01/2026
    HER-2 • ER • PGR
    |
    HER-2 negative
    A Study of ASP1002 in Adults for Treatment of Solid Tumors (NCT05719558)
    Phase 1
    Astellas Pharma Global Development, Inc.
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    03/13/2023
    Primary completion :
    04/30/2028
    Completion :
    05/31/2028
    HER-2 • ER • PGR
    |
    HER-2 negative
    |
    ASP1002
    Converting HR+ Breast Cancer Into an Individualized Vaccine (NCT03804944)
    Phase 2
    Weill Medical College of Cornell University
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    03/17/2020
    Primary completion :
    12/01/2025
    Completion :
    12/01/2027
    HER-2 • PGR
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • Mobista (CDX-301)
    Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, Node Positive, HR+/HER2- Breast Cancer (NCT05996107)
    Phase 1
    University of Michigan Rogel Cancer Center
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    02/27/2024
    Primary completion :
    06/01/2026
    Completion :
    06/01/2030
    HER-2 • ER • PGR
    |
    HER-2 negative
    |
    Kisqali (ribociclib)
    A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors (NCT05836324)
    Phase 1
    Incyte Corporation
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    07/24/2023
    Primary completion :
    12/24/2026
    Completion :
    12/24/2026
    HER-2 • BRAF • ER • PGR • ROS1
    |
    HER-2 negative • ER negative
    |
    INCA33890
    Ph II Study of Pembrolizumab & Eribulin in Patients With HR+/HER2- MBC Previously Treated With Anthracyclines & Taxanes (KELLY) (NCT03222856)
    Phase 2
    MedSIR
    Completed
    Last update posted :
    02/19/2025
    Initiation :
    12/14/2017
    Primary completion :
    10/31/2018
    Completion :
    12/23/2020
    HER-2 • PD-L1 • ER • PGR • TMB
    |
    PD-L1 expression • HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    Keytruda (pembrolizumab) • Halaven (eribulin mesylate)
    Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis (ASPIRE) (NCT03691493)
    Phase 2
    Emory University
    Completed
    Last update posted :
    02/17/2025
    Initiation :
    02/08/2019
    Primary completion :
    10/13/2022
    Completion :
    10/13/2022
    HER-2 • ER • PGR
    |
    ER positive • HER-2 negative • PGR positive
    |
    Ibrance (palbociclib) • fulvestrant • letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)
    CFI-400945 in Patients With Advanced/Metastatic Breast Cancer (NCT03624543)
    Phase 2
    Canadian Cancer Trials Group
    Active, not recruiting
    Last update posted :
    02/17/2025
    Initiation :
    02/14/2019
    Primary completion :
    06/30/2025
    Completion :
    12/31/2025
    HER-2 • PGR • PTEN
    |
    PTEN mutation
    |
    ocifisertib (CFI-400945)
    Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer (NCT03598257)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/17/2025
    Initiation :
    01/18/2019
    Primary completion :
    06/01/2027
    Completion :
    06/01/2027
    ER • PGR • BRCA1 • BRCA2 • BRCA
    |
    BRCA mutation
    |
    Lynparza (olaparib)
    Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer (GeparPiPPa) (NCT05306041)
    Phase 2
    German Breast Group
    Recruiting
    Last update posted :
    02/17/2025
    Initiation :
    01/02/2023
    Primary completion :
    10/01/2026
    Completion :
    01/01/2027
    HER-2 • PIK3CA • PGR
    |
    HER-2 positive • PIK3CA mutation • PGR positive
    |
    Herceptin (trastuzumab) • tamoxifen • Perjeta (pertuzumab) • Itovebi (inavolisib) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)
    A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer (DESTINY-Breast07) (NCT04538742)
    Phase 1/2
    AstraZeneca
    Active, not recruiting
    Last update posted :
    02/14/2025
    Initiation :
    12/28/2020
    Primary completion :
    01/31/2025
    Completion :
    01/31/2030
    HER-2 • PGR
    |
    HER-2 positive • HR positive
    |
    Imfinzi (durvalumab) • paclitaxel • Perjeta (pertuzumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Tukysa (tucatinib)
    HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer (NCT03387553)
    Phase 1
    H. Lee Moffitt Cancer Center and Research Insti...
    Active, not recruiting
    Last update posted :
    02/14/2025
    Initiation :
    06/06/2018
    Primary completion :
    08/29/2026
    Completion :
    08/29/2026
    HER-2 • PGR • CD4
    |
    carboplatin • docetaxel • Perjeta (pertuzumab)
    PALbociclib CoLlaborative Adjuvant Study (PALLAS) (NCT02513394)
    Phase 3
    Alliance Foundation Trials, LLC.
    Active, not recruiting
    Last update posted :
    02/14/2025
    Initiation :
    08/01/2015
    Primary completion :
    11/01/2020
    Completion :
    12/01/2028
    HER-2 • PGR
    |
    HER-2 negative
    |
    Ibrance (palbociclib)
    SMART-ER: Symptom Monitoring With Patient-reported Outcomes (NCT05560685)
    Phase N/A
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Recruiting
    Last update posted :
    02/13/2025
    Initiation :
    10/03/2022
    Primary completion :
    08/01/2025
    Completion :
    11/03/2025
    ER • PGR
    |
    HR positive
    Nadunolimab in Combination with Gemcitabine Plus Carboplatin in Patients with Advanced Triple Negative Breast Cancer. (TRIFOUR) (NCT05181462)
    Phase 1/2
    Cantargia AB
    Recruiting
    Last update posted :
    02/13/2025
    Initiation :
    01/11/2022
    Primary completion :
    06/15/2025
    Completion :
    08/01/2026
    HER-2 • PD-L1 • ER • PGR • BRCA1 • BRCA2 • BRCA
    |
    HER-2 negative • HER-2 negative + HR negative • HER-2 negative + HR negative + BRCA mutation
    |
    carboplatin • gemcitabine • nadunolimab (CAN04)
    Prospective Study of the Prosigna Assay on Neoadjuvant Clinical Decision-making in Women with HR+/Her2- Breast Cancer (NCT03749421)
    Phase N/A
    Dana-Farber Cancer Institute
    Active, not recruiting
    Last update posted :
    02/13/2025
    Initiation :
    03/21/2019
    Primary completion :
    11/29/2023
    Completion :
    12/31/2025
    HER-2 • PGR
    |
    HER-2 negative
    Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC (NCT03439735)
    Phase 2
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Recruiting
    Last update posted :
    02/13/2025
    Initiation :
    07/20/2018
    Primary completion :
    08/01/2025
    Completion :
    11/01/2025
    HER-2 • ER • PGR
    |
    HER-2 negative
    |
    Ibrance (palbociclib)
    Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients with Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery (NCT02760030)
    Phase 2
    Ohio State University Comprehensive Cancer Center
    Active, not recruiting
    Last update posted :
    02/12/2025
    Initiation :
    02/16/2017
    Primary completion :
    07/31/2025
    Completion :
    07/31/2025
    HER-2 • ER • PGR
    |
    HER-2 negative
    |
    Ibrance (palbociclib) • fulvestrant
    A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) (KEYNOTE-F21) (NCT04225117)
    Phase 2
    Astellas Pharma Global Development, Inc.
    Active, not recruiting
    Last update posted :
    02/12/2025
    Initiation :
    03/09/2020
    Primary completion :
    09/30/2026
    Completion :
    09/30/2026
    BRAF • ER • ALK • PGR
    |
    PD-L1 expression • HER-2 positive • ER positive • EGFR mutation • BRAF mutation • HER-2 negative • ER negative • HER-2 negative + ER positive
    |
    Keytruda (pembrolizumab) • Padcev (enfortumab vedotin-ejfv)
    NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III) (NCT06081244)
    Phase 2
    West German Study Group
    Recruiting
    Last update posted :
    02/12/2025
    Initiation :
    10/10/2024
    Primary completion :
    09/01/2029
    Completion :
    09/01/2029
    HER-2 • PGR
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • Trodelvy (sacituzumab govitecan-hziy)
    Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial) (NCT05554354)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/12/2025
    Initiation :
    09/13/2024
    Primary completion :
    11/01/2026
    Completion :
    11/01/2026
    HER-2 • ER • PGR • NF1
    |
    HER-2 negative
    |
    Mektovi (binimetinib) • fulvestrant
    Stand Up to Cancer: MAGENTA (Making Genetic Testing Accessible) (NCT02993068)
    Phase N/A
    M.D. Anderson Cancer Center
    Suspended
    Last update posted :
    02/12/2025
    Initiation :
    04/18/2017
    Primary completion :
    04/18/2026
    Completion :
    04/18/2026
    ER • PGR • BRCA1 • BRCA2 • MLH1 • MSH6 • MSH2 • BRIP1 • RAD51C • RAD51D • BARD1
    |
    PALB2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation
    Adjuvant Therapy with an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer (CASE6119) (NCT04674306)
    Phase 1
    George T. Budd
    Recruiting
    Last update posted :
    02/12/2025
    Initiation :
    10/01/2021
    Primary completion :
    05/01/2025
    Completion :
    11/01/2025
    HER-2 • ER • PGR • BRCA1 • PRL
    |
    HER-2 negative • PALB2 mutation • ER negative
    |
    alpha-lactalbumin vaccine
    Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients (NCT04677816)
    Phase 2
    Wake Forest University Health Sciences
    Recruiting
    Last update posted :
    02/12/2025
    Initiation :
    10/22/2021
    Primary completion :
    03/01/2026
    Completion :
    03/01/2026
    HER-2 • PGR
    |
    HER-2 negative • ER negative
    |
    carboplatin • paclitaxel • doxorubicin hydrochloride • cyclophosphamide
    Diet Modification in pAtients With Luminal Early Breast Cancer Candidate for Primary Surgery (MACS) (NCT04469296)
    Phase N/A
    Institut du Cancer de Montpellier - Val d'Aurelle
    Recruiting
    Last update posted :
    02/11/2025
    Initiation :
    05/18/2021
    Primary completion :
    04/01/2026
    Completion :
    04/01/2026
    HER-2 • ER • PGR
    |
    HER-2 negative • PGR positive
    Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to ER+/HER-2- Breast Cancer (ELECTRA) (NCT05386108)
    Phase 1/2
    Stemline Therapeutics, Inc.
    Recruiting
    Last update posted :
    02/11/2025
    Initiation :
    08/31/2022
    Primary completion :
    12/01/2025
    Completion :
    12/01/2025
    HER-2 • ER • PGR
    |
    ER positive • HER-2 negative • HER-2 negative + ER positive
    |
    Verzenio (abemaciclib) • Orserdu (elacestrant)
    Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer (NCT04491942)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/10/2025
    Initiation :
    08/25/2021
    Primary completion :
    06/30/2025
    Completion :
    06/30/2025
    HER-2 • ER • PGR
    |
    HER-2 negative
    |
    cisplatin • gemcitabine • elimusertib (BAY 1895344) • liposomal gemcitabine (FF-10832)
    Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer (NCT02779855)
    Phase 1/2
    H. Lee Moffitt Cancer Center and Research Insti...
    Active, not recruiting
    Last update posted :
    02/10/2025
    Initiation :
    05/02/2017
    Primary completion :
    09/20/2020
    Completion :
    03/31/2025
    HER-2 • ER • PGR
    |
    HER-2 amplification
    |
    paclitaxel • Imlygic (talimogene laherparepvec)
    Evaluating the Safety and Efficacy of a Novel Accelerated Partial Breast Irradiation Regimen (APBI RISE) (NCT05591547)
    Phase 2
    Sanford Health
    Active, not recruiting
    Last update posted :
    02/10/2025
    Initiation :
    03/30/2022
    Primary completion :
    06/01/2027
    Completion :
    06/01/2027
    HER-2 • PGR
    Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy (NCI-2018-01297) (NCT02971748)
    Phase 2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    02/10/2025
    Initiation :
    01/26/2017
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    HER-2 • PD-L1 • ER • PGR
    |
    HER-2 negative • HER-2 negative + ER positive
    |
    Keytruda (pembrolizumab)